Antidiabetes drugs semaglutide and tirzepatide potentially lower dementia and stroke risk by up to 37% in patients with type 2 diabetes and obesity.
“These benefits were even greater among people over age 60, women, and those with a body mass index between 30 and 40. However, the risk of Parkinson's disease and brain bleeds did not differ between the groups.”